Colorectal cancer liver metastases: Diagnostic performance and prognostic value of pet/mr imaging

Radiology

Volumn 280, Issue 3, 2016, Pages 782-792

  Lee, Dong Ho ^a,d   Lee, Jeong Min ^a,d   Hur, Bo Yun ^d,e   Joo, Ijin ^a   Yi, Nam Joon ^b   Suh, Kyung Suk ^b   Kang, Keon Wook ^c   Han, Joon Koo ^a,d  

^a Departments of Radiology   (United States)

^b Department of Surgery ^*  (United States)

^c Seoul National University Hospital   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

^e National Cancer Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GADOXETIC ACID; IRINOTECAN; OXALIPLATIN; CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; COLORECTAL CANCER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ECHOGRAPHY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIVER BIOPSY; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PET-MRI SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SURVIVAL RATE; WHOLE BODY PET; COLORECTAL TUMOR; DIAGNOSTIC IMAGING; LIVER NEOPLASMS; MIDDLE AGED; MULTIMODAL IMAGING; PATHOLOGY; SECONDARY; VERY ELDERLY; WHOLE BODY IMAGING;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; CONTRAST MEDIA; FEMALE; FLUORODEOXYGLUCOSE F18; GADOLINIUM DTPA; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SURVIVAL RATE; WHOLE BODY IMAGING;

EID: 84986197792     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2016151975     Document Type: Article

References (35)

1. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 2006;244(2):254-259.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60(5): 277-300.
3. Robertson DJ, Stukel TA, Gottlieb DJ, Sutherland JM, Fisher ES. Survival after hepatic resection of colorectal cancer metastases: a national experience. Cancer 2009;115(4): 752-759.
4. de Haas RJ, Wicherts DA, Salloum C, et al. Long-term outcomes after hepatic resection for colorectal metastases in young patients. Cancer 2010;116(3):647-658.
5. de Haas RJ, Wicherts DA, Andreani P, et al. Impact of expanding criteria for resectability of colorectal metastases on shortand long-term outcomes after hepatic resection. Ann Surg 2011;253(6):1069-1079.
6. Belli G, D'Agostino A, Ciciliano F, Fantini C, Russolillo N, Belli A. Liver resection for hepatic metastases: 15 years of experience. J Hepatobiliary Pancreat Surg 2002;9(5):607-613.
7. Smith MD, McCall JL. Systematic review of tumour number and outcome after radical treatment of colorectal liver metastases. Br J Surg 2009;96(10):1101-1113.
8. Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005;23(9):2038-2048.
9. Lee KH, Lee JM, Park JH, et al. MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent gadoxetic acid. Korean J Radiol 2013;14(6):894-904.
10. van Kessel CS, Buckens CF, van den Bosch MA, van Leeuwen MS, van Hillegersberg R, Verkooijen HM. Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis. Ann Surg Oncol 2012;19(9):2805-2813.
11. Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology 2010;257(3):674-684.
12. Zech CJ, Herrmann KA, Reiser MF, Schoenberg SO. MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA. Magn Reson Med Sci 2007;6(1):43-52.
13. Maffione AM, Lopci E, Bluemel C, Giammarile F, Herrmann K, Rubello D. Diagnostic accuracy and impact on management of (18)F-FDG PET and PET/CT in colorectal liver metastasis: a meta-analysis and systematic review. Eur J Nucl Med Mol Imaging 2015;42(1):152-163.
14. Yu MH, Lee JM, Hur BY, et al. Gadoxetic acid-enhanced MRI and diffusion-weighted imaging for the detection of colorectal liver metastases after neoadjuvant chemotherapy. Eur Radiol 2015;25(8):2428-2436.
15. Chung WS, Kim MJ, Chung YE, et al. Comparison of gadoxetic acid-enhanced dynamic imaging and diffusion-weighted imaging for the preoperative evaluation of colorectal liver metastases. J Magn Reson Imaging 2011; 34(2):345-353.
16. Findlay M, Young H, Cunningham D, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 1996;14(3):700-708.
17. de Geus-Oei LF, Vriens D, van Laarhoven HW, van der Graaf WT, Oyen WJ. Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med 2009;50(Suppl 1): 43S-54S.
18. Choi M, Kollepara SL, Heilbrun LK, Smith D, Shields AF, Philip PA. PET scans as a predictive marker of survival in advanced colorectal cancer. Clin Colorectal Cancer 2015; 14(1):35-40.
19. Yoo HJ, Lee JS, Lee JM. Integrated whole body MR/PET: where are we? Korean J Radiol 2015;16(1):32-49.
20. Buchbender C, Heusner TA, Lauenstein TC, Bockisch A, Antoch G. Oncologic PET/MRI. I. Tumors of the brain, head and neck, chest, abdomen, and pelvis. J Nucl Med 2012; 53(6):928-938.
21. Buchbender C, Heusner TA, Lauenstein TC, Bockisch A, Antoch G. Oncologic PET/MRI. II. Bone tumors, soft-tissue tumors, melanoma, and lymphoma. J Nucl Med 2012;53(8): 1244-1252.
22. Ba-Ssalamah A, Uffmann M, Saini S, Bastati N, Herold C, Schima W. Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions. Eur Radiol 2009; 19(2):342-357.
23. Danet IM, Semelka RC, Leonardou P, et al. Spectrum of MRI appearances of untreated metastases of the liver. AJR Am J Roentgenol 2003;181(3):809-817.
24. Chakraborty DP. Analysis of location specific observer performance data: validated extensions of the jackknife free-response (JAFROC) method. Acad Radiol 2006;13(10): 1187-1193.
25. Kim SH, Lee JM, Kim YJ, et al. Detection of hepatocellular carcinoma on CT in liver transplant candidates: comparison of PACS tile and multisynchronized stack modes. AJR Am J Roentgenol 2007;188(5):1337-1342.
26. Shin NY, Kim MJ, Lim JS, et al. Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases. Eur Radiol 2012;22(4):864-871.
27. Macera A, Lario C, Petracchini M, et al. Staging of colorectal liver metastases after preoperative chemotherapy. diffusion-weighted imaging in combination with Gd-EOB-DTPA MRI sequences increases sensitivity and di-agnostic accuracy. Eur Radiol 2013;23(3): 739-747.
28. Lubezky N, Metser U, Geva R, et al. The role and limitations of 18-fluoro-2-deoxy-Dglucose positron emission tomography (FDG PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg 2007;11(4):472-478.
29. Angliviel B, Benoist S, Penna C, et al. Impact of chemotherapy on the accuracy of computed tomography scan for the evaluation of colorectal liver metastases. Ann Surg Oncol 2009;16(5):1247-1253.
30. Spatz J, Holl G, Sciuk J, Anthuber M, Arnholdt HM, Märkl B. Neoadjuvant chemotherapy affects staging of colorectal liver metastasis: a comparison of PET, CT and intraoperative ultrasound. Int J Colorectal Dis 2011;26(2):165-171.
31. Akhurst T, Kates TJ, Mazumdar M, et al. Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol 2005;23 (34):8713-8716.
32. Seo HJ, Kim MJ, Lee JD, Chung WS, Kim YE. Gadoxetate disodium-enhanced magnetic resonance imaging versus contrastenhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases. Invest Radiol 2011;46(9):548-555.
33. Lake ES, Wadhwani S, Subar D, et al. The influence of FDG PET-CT on the detection of extrahepatic disease in patients being considered for resection of colorectal liver metastasis. Ann R Coll Surg Engl 2014;96(3):211-215.
34. Lau LF, Williams DS, Lee ST, Scott AM, Christophi C, Muralidharan V. Metabolic response to preoperative chemotherapy predicts prognosis for patients undergoing surgical resection of colorectal cancer metastatic to the liver. Ann Surg Oncol 2014;21(7):2420-2428.
35. Tan MC, Linehan DC, Hawkins WG, Siegel BA, Strasberg SM. Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg 2007;11(9):1112-1119.